Literature DB >> 33819364

Evaluation of Pancreatic Fibrosis Grading by Multimodal Functional Magnetic Resonance Imaging.

Chang Liu1, Yu Shi1, Gongyu Lan1, Youli Xu1, Fei Yang1,2.   

Abstract

BACKGROUND: Early detection and grading of pancreatic fibrosis (PF) are important and challenging clinical goals.
PURPOSE: To determine main pancreatic duct (MPD) diameter, pancreatic thickness, and grades of PF via magnetic resonance elastography (MRE), T1 mapping, and intravoxel incoherent motion diffusion-weighted imaging (IVIM-DWI), assessing respective diagnostic performances. STUDY TYPE: Prospective.
SUBJECTS: Histopathologic and imaging records (MRE, T1 mapping, and IVIM-DWI) generated by 144 patients between December 2018 and May 2020 were collected for analysis. Grades of PF were distributed as follows: F0, 82; F1, 22; F2, 22; and F3, 18. FIELD STRENGTH/SEQUENCE: 3 T pancreatic MRI, encompassing MRE, T1 mapping, and IVIM-DWI. ASSESSMENT: In all patients, T1 relaxation times, pancreatic stiffness values, IVIM-DWI parameters, MPD diameter, and pancreatic thickness were measured. STATISTICAL TESTS: Receiver operating characteristic (ROC) analysis served to assess imaging parameters useful in diagnosing PF. To identify relations between specific parameters and grades of PF, logistic regression analysis was invoked.
RESULTS: Both pancreatic stiffness (r = 0.754; P < 0.001) and T1 relaxation time (r = 0.433; P < 0.001) correlated significantly with PF (%). To determine PF grades ≥F1, a combined model (area under the curve [AUC] = 0.906) performed significantly better than pancreatic stiffness (AUC = 0.855; P < 0.001) or T1 relaxation time (AUC = 0.754; P < 0.001) alone. For PF grades ≥F2 or grade F3, both the combined model (≥F2: AUC = 0.910; F3: AUC = 0.939) and pancreatic stiffness (≥F2: AUC = 0.906; F3: AUC = 0.929) outperformed T1 relaxation time (≥F2: AUC = 0.768 [P = 0.005 and P = 0.004, respectively]; F3: AUC = 0.816 [both P < 0.005]). All IVIM-DWI parameters generated AUC values <0.700. DATA
CONCLUSION: A combination of MRE and T1 mapping seems promising in diagnosing various grades of PF, particularly at an early stage. LEVEL OF EVIDENCE: 1 TECHNICAL EFFICACY: Stage 2.
© 2021 International Society for Magnetic Resonance in Medicine.

Entities:  

Keywords:  T1 mapping; intravoxel incoherent motion; magnetic resonance elastography; pancreatic fibrosis

Year:  2021        PMID: 33819364     DOI: 10.1002/jmri.27626

Source DB:  PubMed          Journal:  J Magn Reson Imaging        ISSN: 1053-1807            Impact factor:   4.813


  3 in total

1.  T1 signal intensity ratio of the pancreas as an imaging biomarker for the staging of chronic pancreatitis.

Authors:  Temel Tirkes; Anil K Dasyam; Zarine K Shah; Evan L Fogel; Santhi Swaroop Vege; Liang Li; Shuang Li; Stephanie T Chang; Carlos A Farinas; Joseph R Grajo; Kareem Mawad; Naoki Takahashi; Sudhakar K Venkatesh; Ashley Wachsman; William E Fisher; Christopher E Forsmark; Phil A Hart; Stephen J Pandol; Walter G Park; Stephen K Van Den Eeden; Yunlong Yang; Mark Topazian; Dana K Andersen; Jose Serrano; Darwin L Conwell; Dhiraj Yadav
Journal:  Abdom Radiol (NY)       Date:  2022-07-20

2.  Histopathologic correlation of pancreatic fibrosis with pancreatic magnetic resonance imaging quantitative metrics and Cambridge classification.

Authors:  Temel Tirkes; Omer A Saeed; Vitalis C Osuji; Carsyn E Kranz; Adam A Roth; Aashish A Patel; Nicholas J Zyromski; Evan L Fogel
Journal:  Abdom Radiol (NY)       Date:  2022-04-29

3.  Quantitative MRI of chronic pancreatitis: results from a multi-institutional prospective study, magnetic resonance imaging as a non-invasive method for assessment of pancreatic fibrosis (MINIMAP).

Authors:  Temel Tirkes; Dhiraj Yadav; Darwin L Conwell; Paul R Territo; Xuandong Zhao; Scott A Persohn; Anil K Dasyam; Zarine K Shah; Sudhakar K Venkatesh; Naoki Takahashi; Ashley Wachsman; Liang Li; Yan Li; Stephen J Pandol; Walter G Park; Santhi S Vege; Phil A Hart; Mark Topazian; Dana K Andersen; Evan L Fogel
Journal:  Abdom Radiol (NY)       Date:  2022-08-29
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.